Welcome to the ALDA Pharmaceuticals Hub on AGORACOM

(Edit this message through the "fast facts" section)

Free
Message: YES---Today after the bell

TSX VENTURE COMPANIES

ALDA PHARMACEUTICALS CORP. ("APH")
BULLETIN TYPE: Private Placement-Non-Brokered
BULLETIN DATE: September 9, 2009
TSX Venture Tier 2 Company

TSX Venture Exchange has accepted for filing documentation with respect to
a Non-Brokered Private Placement announced July 3, 2009 and amended July 17,
2009:

Number of Shares: 6,000,000 shares

Purchase Price: $0.25 per share

Warrants: 6,000,000 share purchase warrants to purchase
6,000,000 shares

Warrant Exercise Price: $0.40 for a one year period subject to an
accelerated exercise provision where if, for
10 consecutive trading days, the closing price
of the listed shares of the Company exceeds
$0.80 per share then the exercise period of the
warrants will be reduced to a period of 10 days
following such trading days.

Number of Placees: 83 placees

Insider/Pro Group Participation:

Insider equals Y/
Name ProGroup equals P/ No. of Shares

Pamela Mann P 10,000
Jason Gold P 32,000
Eugene Hodgson Y 50,000
David Murdoch P 20,000
Mike Siggs P 20,000
Valerie Siggs P 40,000
Ray Martin P 50,000

Finder's Fee: $625 in cash payable to Research Capital Corp.
$3,437.50 in cash payable to Canaccord Capital
Corp.
$15,000 in cash payable to Northern Securities
Inc.
$5,275 in cash payable to Pure Marketing &
Advertisign Inc.
$2,500 in cash payable to CIBC Wood Gundy
$2,500 in cash payable to Scotia McLeod
$5,000 in cash payable to John Gallagher

Pursuant to Corporate Finance Policy 4.1, Section 1.11(d), the Company
must issue a news release announcing the closing of the private placement and
setting out the expiry dates of the hold period(s). The Company must also
issue a news release if the private placement does not close promptly. Note
that in certain circumstances the Exchange may later extend the expiry date of
the warrants, if they are less than the maximum permitted term.

TSX-X
----------------------------------

Share
New Message
Please login to post a reply